Literature DB >> 26136934

Pediatric patients with inflammatory bowel disease exhibit increased serum levels of proinflammatory cytokines and chemokines, but decreased circulating levels of macrophage inhibitory protein-1β, interleukin-2 and interleukin-17.

Giulio Kleiner1, Valentina Zanin1, Lorenzo Monasta1, Sergio Crovella2, Lorenzo Caruso3, Daniela Milani3, Annalisa Marcuzzi1.   

Abstract

Inflammatory bowel disease (IBD) is a chronic and progressive inflammatory condition of the gastrointestinal tract. Although the causative events that lead to the onset of IBD are yet to be fully elucidated, deregulation of immune and inflammatory mechanisms are hypothesized to significantly contribute to this disorder. Since the onset of IBD is often during infancy, in the present study, the serum values of a large panel of cytokines and chemokines in pediatric patients (<18 years; n=26) were compared with age-matched controls (n=37). While elevations in the serum level of several proinflammatory and immune regulating cytokines were confirmed, such as interleukin (IL)-1β, IL-5, IL-7, interferon (IFN)-γ-inducible protein-10, IL-16, cutaneous T-cell-attracting chemokine, leukemia inhibitory factor, monokine induced by γ-IFN, IFN-α2 and IFN-γ, notably decreased levels of IL-2, IL-17 and macrophage inhibitory protein-1β were also observed. Therefore, while a number of proinflammatory cytokines exhibit increased levels in IBD patients, pediatric IBD patients may also exhibit certain aspects of a reduced immunological response.

Entities:  

Keywords:  chemokines; cytokines; inflammatory bowel disease

Year:  2015        PMID: 26136934      PMCID: PMC4473502          DOI: 10.3892/etm.2015.2370

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  35 in total

Review 1.  Inflammatory bowel disease.

Authors:  Daniel K Podolsky
Journal:  N Engl J Med       Date:  2002-08-08       Impact factor: 91.245

2.  Interleukin-1beta and the autoinflammatory diseases.

Authors:  Charles A Dinarello
Journal:  N Engl J Med       Date:  2009-06-04       Impact factor: 91.245

3.  Elevated levels of Th17 cells and Th17-related cytokines are associated with disease activity in patients with inflammatory bowel disease.

Authors:  Wenyu Jiang; Jiewen Su; Xiaofei Zhang; Xiuqin Cheng; Jun Zhou; Ruihua Shi; Hongjie Zhang
Journal:  Inflamm Res       Date:  2014-08-18       Impact factor: 4.575

Review 4.  Inhibition of IL-17 as a pharmacological approach for IBD.

Authors:  Leo R Fitzpatrick
Journal:  Int Rev Immunol       Date:  2013-07-25       Impact factor: 5.311

5.  Increased expression of IL-16 in inflammatory bowel disease.

Authors:  D Seegert; P Rosenstiel; H Pfahler; P Pfefferkorn; S Nikolaus; S Schreiber
Journal:  Gut       Date:  2001-03       Impact factor: 23.059

6.  TGF-beta1 production in inflammatory bowel disease: differing production patterns in Crohn's disease and ulcerative colitis.

Authors:  B Del Zotto; G Mumolo; A M Pronio; C Montesani; R Tersigni; M Boirivant
Journal:  Clin Exp Immunol       Date:  2003-10       Impact factor: 4.330

7.  Increased prevalence of circulating novel IL-17 secreting Foxp3 expressing CD4+ T cells and defective suppressive function of circulating Foxp3+ regulatory cells support plasticity between Th17 and regulatory T cells in inflammatory bowel disease patients.

Authors:  Aito Ueno; Humberto Jijon; Ronald Chan; Kim Ford; Christina Hirota; Gilaad G Kaplan; Paul L Beck; Marietta Iacucci; Miriam Fort Gasia; Herman W Barkema; Remo Panaccione; Subrata Ghosh
Journal:  Inflamm Bowel Dis       Date:  2013-11       Impact factor: 5.325

8.  Glutamine and CXC chemokines IL-8, Mig, IP-10 and I-TAC in human intestinal epithelial cells.

Authors:  Rachel Marion; M Moïse Coëffier; Gilles Gargala; Philippe Ducrotté; P Pierre Déchelotte
Journal:  Clin Nutr       Date:  2004-08       Impact factor: 7.324

9.  Differential in situ expression of the genes encoding the chemokines MCP-1 and RANTES in human inflammatory bowel disease.

Authors:  L Mazzucchelli; C Hauser; K Zgraggen; H E Wagner; M W Hess; J A Laissue; C Mueller
Journal:  J Pathol       Date:  1996-02       Impact factor: 7.996

10.  Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment.

Authors:  Cornelia Tillack; Laura Maximiliane Ehmann; Matthias Friedrich; Rüdiger P Laubender; Pavol Papay; Harald Vogelsang; Johannes Stallhofer; Florian Beigel; Andrea Bedynek; Martin Wetzke; Harald Maier; Maria Koburger; Johanna Wagner; Jürgen Glas; Julia Diegelmann; Sarah Koglin; Yvonne Dombrowski; Jürgen Schauber; Andreas Wollenberg; Stephan Brand
Journal:  Gut       Date:  2013-03-06       Impact factor: 23.059

View more
  8 in total

1.  Gut-Liver Physiomimetics Reveal Paradoxical Modulation of IBD-Related Inflammation by Short-Chain Fatty Acids.

Authors:  Martin Trapecar; Catherine Communal; Jason Velazquez; Christian Alexander Maass; Yu-Ja Huang; Kirsten Schneider; Charles W Wright; Vincent Butty; George Eng; Omer Yilmaz; David Trumper; Linda G Griffith
Journal:  Cell Syst       Date:  2020-03-18       Impact factor: 10.304

2.  Exosomes Derived from Human Umbilical Cord Mesenchymal Stem Cells Relieve Inflammatory Bowel Disease in Mice.

Authors:  Fei Mao; Yunbing Wu; Xudong Tang; Jingjing Kang; Bin Zhang; Yongmin Yan; Hui Qian; Xu Zhang; Wenrong Xu
Journal:  Biomed Res Int       Date:  2017-05-15       Impact factor: 3.411

3.  Serum interleukin 17A and interleukin 17F in children with inflammatory bowel disease.

Authors:  Paulina Krawiec; Elżbieta Pac-Kożuchowska
Journal:  Sci Rep       Date:  2020-07-28       Impact factor: 4.379

Review 4.  Regulation of Nuclear Factor Kappa-Light-Chain-Enhancer of Activated B Cells (NF-κβ) in Inflammatory Bowel Diseases.

Authors:  Deenaz Zaidi; Eytan Wine
Journal:  Front Pediatr       Date:  2018-10-30       Impact factor: 3.418

5.  Human physiomimetic model integrating microphysiological systems of the gut, liver, and brain for studies of neurodegenerative diseases.

Authors:  Martin Trapecar; Emile Wogram; Devon Svoboda; Catherine Communal; Attya Omer; Tenzin Lungjangwa; Pierre Sphabmixay; Jason Velazquez; Kirsten Schneider; Charles W Wright; Samuel Mildrum; Austin Hendricks; Stuart Levine; Julien Muffat; Meelim Jasmine Lee; Douglas A Lauffenburger; David Trumper; Rudolf Jaenisch; Linda G Griffith
Journal:  Sci Adv       Date:  2021-01-29       Impact factor: 14.136

6.  Short-Term Surveillance of Cytokines and C-Reactive Protein Cannot Predict Efficacy of Fecal Microbiota Transplantation for Ulcerative Colitis.

Authors:  Ting Zhang; Bota Cui; Pan Li; Zhi He; Chuyan Long; Lu Wei; Zhaoyuan Peng; Guozhong Ji; Faming Zhang
Journal:  PLoS One       Date:  2016-06-27       Impact factor: 3.240

7.  Ex vivo response to mucosal bacteria and muramyl dipeptide in inflammatory bowel disease.

Authors:  Claudia Loganes; Erica Valencic; Alessia Pin; Elisa Marini; Stefano Martelossi; Samuele Naviglio; Luigina De Leo; Tarcisio Not; Lorenzo Monasta; Alberto Tommasini; Annalisa Marcuzzi
Journal:  World J Gastroenterol       Date:  2016-11-28       Impact factor: 5.742

8.  Diagnostic Potential of Systemic Eosinophil-Associated Cytokines and Growth Factors in IBD.

Authors:  Katarzyna Neubauer; Malgorzata Matusiewicz; Iwona Bednarz-Misa; Sabina Gorska; Andrzej Gamian; Malgorzata Krzystek-Korpacka
Journal:  Gastroenterol Res Pract       Date:  2018-07-29       Impact factor: 2.260

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.